David A Lipson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/829036/publications.pdf

Version: 2024-02-01

100	3,882	218592	128225
papers	citations	26 h-index	60 g-index

101	101	101	3910
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine, 2018, 378, 1671-1680.	13.9	823
2	A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care, 2017, 21, 234.	2.5	515
3	FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 438-446.	2.5	262
4	Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 659-666.	2.5	160
5	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respiratory Medicine,the, 2019, 7, 745-756.	5.2	159
6	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516.	2.5	151
7	A Combined Pulmonary-Radiology Workshop for Visual Evaluation of COPD: Study Design, Chest CT Findings and Concordance with Quantitative Evaluation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 151-159.	0.7	143
8	Bronchoscopy for Atelectasis in the ICU. Chest, 2003, 124, 344-350.	0.4	105
9	An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. Journal of Clinical Pharmacology, 2012, 52, 416-424.	1.0	99
10	Determination of regional VA/Q by hyperpolarized3He MRI. Magnetic Resonance in Medicine, 2004, 52, 65-72.	1.9	81
11	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research, 2019, 20, 238.	1.4	81
12	Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Advances in Therapy, 2017, 34, 2518-2533.	1.3	79
13	A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. European Respiratory Journal, 2016, 48, 320-330.	3.1	77
14	Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRI. Thorax, 2012, 67, 613-617.	2.7	75
15	Pulmonary ventilation and perfusion scanning using hyperpolarized helium-3 MRI and arterial spin tagging in healthy normal subjects and in pulmonary embolism and orthotopic lung transplant patients. Magnetic Resonance in Medicine, 2002, 47, 1073-1076.	1.9	49
16	Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respiratory Research, 2018, 19, 19.	1.4	46
17	Perfusion Scintigraphy and Patient Selection for Lung Volume Reduction Surgery. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 937-946.	2.5	43
18	Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patients. Digestive Diseases and Sciences, 1998, 43, 1177-1185.	1.1	42

#	Article	IF	Citations
19	Hyperpolarized13C MRI of the pulmonary vasculature and parenchyma. Magnetic Resonance in Medicine, 2007, 57, 459-463.	1.9	38
20	Renal and Vestibular Toxicity Due to Inhaled Tobramycin in a Lung Transplant Recipient. Journal of Heart and Lung Transplantation, 2005, 24, 932-935.	0.3	37
21	Measurements of Regional Alveolar Oxygen Pressure Using Hyperpolarized 3He MRI1. Academic Radiology, 2005, 12, 1430-1439.	1.3	35
22	Detection and localization of pulmonary air leaks using laser-polarized3He MRI. Magnetic Resonance in Medicine, 2000, 44, 379-382.	1.9	30
23	A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome. Critical Care Medicine, 2015, 43, 1859-1869.	0.4	30
24	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1237-1243.	2.5	28
25	Detection of simulated pulmonary embolism in a porcine model using hyperpolarized3He MRI. Magnetic Resonance in Medicine, 2004, 51, 291-298.	1.9	27
26	The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 303, L259-L271.	1.3	27
27	The Evaluation and Preparation of the Patient for Lung Volume Reduction Surgery. Proceedings of the American Thoracic Society, 2008, 5, 427-431.	3.5	26
28	Overview of the Perioperative Management of Lung Volume Reduction Surgery Patients. Proceedings of the American Thoracic Society, 2008, 5, 438-441.	3.5	25
29	³He pO₂ mapping is limited by delayedâ€ventilation and diffusion in chronic obstructive pulmonary disease. Magnetic Resonance in Medicine, 2014, 71, 1172-1178.	1.9	25
30	Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respiratory Research, 2020, 21, 131.	1.4	25
31	The effect of exacerbation history on outcomes in the IMPACT trial. European Respiratory Journal, 2020, 55, 1901921.	3.1	24
32	Dynamic observation of pulmonary perfusion using continuous arterial spinâ€labeling in a pig model. Journal of Magnetic Resonance Imaging, 2001, 14, 175-180.	1.9	23
33	Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. Advances in Therapy, 2018, 35, 56-71.	1.3	22
34	Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Research, 2018, 4, 00047-2018.	1.1	22
35	Apical Perfusion Fraction as a Predictor of Short-term Functional Outcome Following Bilateral Lung Volume Reduction Surgery. Chest, 2001, 120, 1609-1615.	0.4	21
36	Co-registration of acquired MR ventilation and perfusion images?Validation in a porcine model. Magnetic Resonance in Medicine, 2003, 49, 13-18.	1.9	20

#	Article	IF	Citations
37	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Annals of the American Thoracic Society, 2021, 18, 788-798.	1.5	19
38	The IMPACT Study â€“ Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population . International Journal of COPD, 2019, Volume 14, 2849-2861.	0.9	18
39	Measuring disease activity in COPD: is clinically important deterioration the answer?. Respiratory Research, 2020, 21, 134.	1.4	18
40	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. International Journal of COPD, 2021, Volume 16, 499-517.	0.9	17
41	Hyperpolarized helium-3 MR imaging of pulmonary function. Radiologic Clinics of North America, 2005, 43, 235-246.	0.9	16
42	Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Research, 2018, 4, 00119-2017.	1.1	16
43	Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial. Advances in Therapy, 2017, 34, 2163-2172.	1.3	15
44	Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine, 2018, 379, 590-593.	13.9	15
45	Operating Characteristics of Hyperpolarized 3He and Arterial Spin Tagging in MR Imaging of Ventilation and Perfusion in Healthy Subjects. Academic Radiology, 2003, 10, 502-508.	1.3	14
46	Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting Î²2-Agonist Therapy: An Integrated Post Hoc Analysis. Advances in Therapy, 2018, 35, 1626-1638.	1.3	13
47	Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-NaÃ¯ve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Pulmonary Therapy, 2018, 4, 171-183.	1.1	12
48	Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. Pulmonary Pharmacology and Therapeutics, 2019, 57, 101802.	1.1	11
49	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 25-33.	2.5	11
50	Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respiratory Research, 2019, 20, 60.	1.4	10
51	Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Advances in Therapy, 2020, 37, 3775-3790.	1.3	9
52	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respiratory Research, 2020, 21, 139.	1.4	9
53	InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respiratory Research, 2021, 22, 130.	1.4	9
54	Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. International Journal of COPD, 2021, Volume 16, 1255-1264.	0.9	9

#	Article	IF	Citations
55	Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Research, 2018, 4, 00073-2017.	1.1	8
56	Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. International Journal of COPD, 2021, Volume 16, 1215-1226.	0.9	8
57	Tiotropium bromide. International Journal of COPD, 2006, 1, 107-114.	0.9	8
58	Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review, 2021, 30, 210124.	3.0	8
59	The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 334-340.	0.7	7
60	Misinterpretation of time-to-first event curves can lead to inappropriate treatment. European Respiratory Journal, 2019, 54, 1900634.	3.1	7
61	Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096850.	1.0	7
62	Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 773-774.	2.5	7
63	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research, 2021, 7, 00663-2020.	1.1	7
64	Redefining Treatment in COPD. Treatments in Respiratory Medicine, 2004, 3, 89-95.	1.4	6
65	Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials. Drugs and Aging, 2018, 35, 637-647.	1.3	6
66	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD. Chest, 2021, 159, 985-995.	0.4	6
67	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy, 2021, 7, 101-118.	1.1	6
68	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. Npj Primary Care Respiratory Medicine, 2021, 31, 29.	1.1	6
69	Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-NaÃ¯ve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of COPD, 2021, Volume 16, 1939-1956.	0.9	6
70	Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation. Respiratory Medicine, 2021, 187, 106573.	1.3	6
71	Multiple regression method for pulmonary apparent diffusion coefficient measurement by hyperpolarized3He MRI. Journal of Magnetic Resonance Imaging, 2007, 25, 982-991.	1.9	5
72	Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. Journal of Clinical Pharmacology, 2018, 58, 1461-1467.	1.0	5

#	Article	IF	Citations
73	Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Clinical Pharmacokinetics, 2020, 59, 67-79.	1.6	5
74	Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092694.	1.0	4
75	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy, 2021, 38, 4815-4835.	1.3	4
76	A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. European Respiratory Journal, 2021, 58, 2004522.	3.1	4
77	Tension Pneumoperitoneum Associated With a Pleural-Peritoneal Shunt. Chest, 1999, 116, 827-830.	0.4	3
78	Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study . International Journal of COPD, 2020, Volume 15, 809-819.	0.9	3
79	Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial. Current Medical Research and Opinion, 2021, 37, 145-155.	0.9	3
80	Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, , .	0.5	3
81	Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. International Journal of COPD, 2022, Volume 17, 415-426.	0.9	3
82	Reply to Suissa and Ariel: The FULFIL Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 542-543.	2.5	2
83	Reply to: â€˜evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studiesâ€™. Expert Review of Respiratory Medicine, 2021, 15, 577-578.	1.0	2
84	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	0.9	2
85	Teaching Case: Improvement of Chronic Chylous Pleural Effusion Using a Restricted Fat Diet and Medium Chain Triglycerides in a Patient with Congenital Lymphangiectasia. Nutrition in Clinical Practice, 2000, 15, 127-129.	1.1	1
86	Gastrointestinal Complications of Acute Respiratory Failure. Clinical Pulmonary Medicine, 2003, 10, 80-84.	0.3	1
87	Reply: â€œFULFIL an Unmet Need in Chronic Obstructive Pulmonary Diseaseâ€•and â€œTriple Therapy in Chronic Obstructive Pulmonary Diseaseâ€• American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1083-1084.	2.5	1
88	Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1230-1231.	2.5	1
89	24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study. Advances in Therapy, 2020, 37, 4894-4909.	1.3	1
90	Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096302.	1.0	1

#	Article	IF	Citations
91	Letter to editor â€“ a response to: â€˜efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert reviewâ€™. Expert Opinion on Pharmacotherapy, 2021, 22, 939-941.	0.9	1
92	Reply to LÃ³pez-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 928-929.	2.5	1
93	InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone) Tj ETQq1 1 0.784314 rgBT /Over in Patients With COPD: Analysis of the Western Europe and North America Regions. Chronic Obstructive Pulmonary Diseases (Miami, Fla.), 2021, 8, 76-90.	0.5	1
94	Post-mortem stability of thyrotropin-releasing hormone and muscarinic cholinergic receptors in rat forebrain. Synapse, 1989, 4, 387-389.	0.6	0
95	Locating and Selecting Appraisal Studies for Reviews. Chest, 2004, 125, 799.	0.4	0
96	Surgical Options in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine, 2006, 13, 1-7.	0.3	0
97	Reply to: â€œIntraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studiesâ€•[Letter]. International Journal of COPD, 2021, Volume 16, 1299-1301.	0.9	0
98	Functional magnetic resonance imaging of the lung. , 0, , 41-48.		0
99	Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review. Journal for Nurse Practitioners, 2022, , .	0.4	0
100	Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine, 2022, , 106918.	1.3	0